After obtaining her masters in neuromolecular genetic at the Institute for Genetics and Cellular and Molecular Biology, Strasbourg (France), Dr. Ramboz went on to pursue neuropharmacological research at Columbia University. There, she obtained her PhD thesis under the supervision of Dr. Rene Hen on the genetic and behavioral roles of serotonin (chemical messenger) receptors by generating pre-cinical models. Thereafter, Dr. Ramboz joined the biothechnology industry by founding Memory Pharmaceuticals, focusing at that time on dopamine receptors and their roles in aging. She then worked at Xenogen Biosciences Corporation and worked on generating and characterizing pre-clinical models of central nervous system (CNS) diseases. Dr. Ramboz brings more than 20 years of expertise in neuromolecular, neuropharmacology and CNS behavior and leads the neurodegenerative disorders program at PsychoGenics, where she is responsible for the scientific, operational and business development of spinal muscular atrophy, muscular dystrophies, Huntington and Parkinson disease projects.